zinc finger protein 32Genealiases: KOX30 · ZNF637 · Zfp637
Q-omics provides the consensus-scored ZNF32 profile across patient tissues and cancer cell-line models. ZNF32 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF32 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, ZNF32 RNA expression shows 18,294 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KICH, and UVM as cancer lineages where ZNF32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF32 survival associations across molecular data types. ZNF32 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF32 RNA expression–survival associations across cancer types. High ZNF32 expression shows unfavorable associations in SCLC and LIHC, but favorable associations in MESO, PAAD, OV and LGG. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF32 RNA expression.
This table summarizes ZNF32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF32 shows lower tumor expression in KICH, THCA, UCEC and LUSC and higher tumor expression in LIHC and CHOL. The KICH box plot shows higher ZNF32 RNA expression in normal versus tumor tissue (log2 FC = −1.899, t-test p < 0.001).
This table shows molecular features associated with ZNF32 in patient tissues and cancer cell lines. In patient samples, ZNF32 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
